SUPPORT for Patients and Communities Reauthorization Act of 2025
Click any stage to learn more about the legislative process.
The SUPPORT for Patients and Communities Reauthorization Act of 2025 reauthorizes, through fiscal year 2030, dozens of federal grant and treatment programs that address opioid and other substance use disorders, including prevention grants, residential treatment for pregnant women, peer recovery support, and loan repayment for addiction treatment providers.
It also adds new safeguards, directing HHS to protect the 9-8-8 Suicide Prevention Lifeline from cybersecurity threats, creating a federal work group on fentanyl-contaminated illegal drugs, and requiring a review of the drug scheduling of buprenorphine-naloxone combination products, extending the government's multi-year response to the overdose crisis.
What this law does
What it does
The law reauthorizes, generally for fiscal years 2026 through 2030, a broad set of Department of Health and Human Services programs created or extended by the original 2018 SUPPORT Act, covering prenatal and postnatal substance use disorder care, overdose monitoring, first responder training, child trauma treatment, residential treatment for pregnant and postpartum women, addiction medicine workforce loan repayment, peer recovery support centers, and youth prevention grants, with updated funding levels for each. It also revises several programs' scope, such as letting first responder grants cover non-opioid overdose treatment devices and letting workforce recovery grants pay for participant transportation.
Beyond reauthorization, it creates new requirements: HHS must protect the 9-8-8 Suicide Prevention Lifeline from cybersecurity incidents and report vulnerabilities, a Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs must be established, HHS must review whether to reschedule approved buprenorphine-naloxone products, and several one-time studies, reports, and public meetings are required on drug disposal guidance, opioid drug assessment, and health information technology adoption in behavioral health care.
Key provisions
- 1Reauthorizes numerous Public Health Service Act grant programs addressing prenatal substance exposure, overdose prevention, first responder training, and child trauma through fiscal year 2030 with updated funding levels.
- 2Reauthorizes and revises treatment programs including residential care for pregnant and postpartum women, addiction medicine training, and the loan repayment program for substance use disorder treatment providers.
- 3Reauthorizes recovery programs including community recovery organizations, peer support technical assistance, comprehensive opioid recovery centers, and youth prevention and recovery grants.
- 4Requires HHS to protect the 9-8-8 Suicide Prevention Lifeline from cybersecurity incidents and imposes vulnerability and incident reporting requirements on the program's network administrator and local crisis centers.
- 5Establishes a Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs to study and recommend responses to fentanyl-laced drug overdoses.
- 6Directs HHS to review the scheduling of approved buprenorphine-naloxone combination products under the Controlled Substances Act and request rescheduling if appropriate.
- 7Revises pharmacy delivery and prescriber training requirements under the Controlled Substances Act, including expanding eligible professional organizations that can provide required training.
Who is affected
Pregnant and postpartum women, youth, and adults with substance use disorders who rely on federally funded treatment and recovery programs; state, tribal, and local governments and nonprofits that receive SAMHSA and HHS grants; addiction medicine providers and medical students eligible for loan repayment or training grants; first responders; and users of the 9-8-8 Suicide Prevention Lifeline.
Why it matters
Without reauthorization, dozens of opioid and mental health programs created under the 2018 SUPPORT Act would have lost their funding authorization after fiscal year 2023, disrupting grants states and providers rely on. The new cybersecurity, fentanyl work group, and drug-scheduling review provisions add oversight mechanisms responding to evolving risks in the overdose crisis, such as fentanyl contamination and hotline security.
What changed
Changes to existing law
Reauthorizes Public Health Service Act
Extends funding authorizations for numerous prevention, treatment, and recovery grant programs through fiscal year 2030 with revised dollar amounts.
Amends SUPPORT for Patients and Communities Act (Public Law 115-271)
Reauthorizes many of its programs through 2030, revises eligibility and grant terms, and adds the Fentanyl Contamination Work Group.
Amends Controlled Substances Act (Sec. 401, Sec. 402)
Revises rules for pharmacy delivery of controlled substances to prescribers and expands recognized organizations for required prescriber training.
Amends 21st Century Cures Act (Sec. 113)
Allows State and Tribal opioid response grant funds to be used for fentanyl and xylazine test strips to detect drug contamination.
Agencies directed to act
Effective dates
- Comptroller General study on Suicide Prevention Lifeline cybersecurity risks must be completed and reported
- HHS guidance on at-home drug disposal systems must be published
- FDA report outlining plan for assessing opioid analgesic drugs must be published
- Public roundtable on health information technology in mental health/substance use care must be convened
- Amendments to prescriber training organization requirements
- Interdepartmental Substance Use Disorders Coordinating Committee terminates
Funding and costs
- $505,579,000
grants to prevent overdoses of controlled substances and monitor associated risk factors
- $12,500,000
fetal alcohol spectrum disorder prevention, intervention, and services program
- $57,000,000
first responder training program for overdose response
- $98,887,000 (FY2026-2028), $100,000,000 (FY2029-2030)
Donald J. Cohen National Child Traumatic Stress Initiative
- $9,000,000
monitoring and reporting of child, youth, and adult trauma
- $38,931,000
residential treatment programs for pregnant and postpartum women
- $40,000,000
loan repayment program for substance use disorder treatment workforce
- $17,000,000
building communities of recovery grant program
- $2,000,000
peer support technical assistance center, including a regional center
- $10,000,000 to $15,000,000 (increasing annually)
youth substance use disorder prevention and recovery grants
- $12,000,000
CAREER Act treatment, recovery, and workforce support grants
How it works
HHS agencies (SAMHSA, CDC, FDA, HRSA offices) continue administering the reauthorized grant programs through existing application and award cycles, now funded through FY2030. New provisions add reporting layers: the Suicide Prevention Lifeline's network administrator and local crisis centers must report cybersecurity vulnerabilities to HHS; the Interdepartmental Coordinating Committee must stand up a Fentanyl Work Group that consults stakeholders and reports annually to HHS and Congress; HHS must review buprenorphine-naloxone scheduling and, if warranted, ask the Attorney General to initiate rulemaking; and several one-time studies, reports, and public meetings (drug disposal guidance, opioid analgesic assessment, health IT roundtable, block grant funding review) carry fixed deadlines tied to enactment.
Legislative status & sources
Latest action
Became Public Law No: 119-44.
Official CRS summary
Show the CRS summaryHide the CRS summary
This bill reauthorizes and revises Department of Health and Human Services (HHS) programs that address substance use disorders, overdoses, and mental health.
For example, the bill reauthorizes for FY2026-FY2030 grant and other programs relating to
• addressing substance use disorders with respect to pregnant and postpartum women,
• prevention and recovery from substance use disorders for youth,
• housing for individuals in recovery from substance use disorders,
• community organizations facilitating recovery from substance use disorders,
• loan repayment for certain health care providers treating substance use disorders,
• prevention of overdoses of controlled substances,
• treatment of children experiencing psychological trauma, and
• mental and behavioral health education and training for medical and allied health students.
Also, the bill revises several programs, including by (1) expanding a program that supports resources for first responders to include the purchase of drugs or devices to treat non-opioid overdoses, (2) expanding a program that supports employment services for individuals in recovery so as to allow for the provision of related transportation services, and (3) temporarily authorizing a regional technical assistance center to assist the National Peer-Run Training and Technical Assistance Center for Addiction Recovery Support.
Additionally, the bill establishes new requirements for HHS, including requirements relating to
• protecting the National Suicide Prevention Lifeline program from cybersecurity threats,
• establishing a Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs, and
• reviewing and potentially revising the scheduling of approved products containing a combination of buprenorphine and naloxone under the Controlled Substances Act.
Legislative subjects
Advisory bodies; Child health; Community life and organization; Computer security and identity theft; Congressional oversight; Drug trafficking and controlled substances; Drug, alcohol, tobacco use; Emergency communications systems; Employment and training programs; Family services; First responders and emergency personnel; Government information and archives; Government lending and loan guarantees; Government studies and investigations; Health; Health care coverage and access; Health information and medical records; Health personnel; Health programs administration and funding; Health promotion and preventive care; Higher education; Housing and community development funding; Intergovernmental relations; Long-term, rehabilitative, and terminal care; Medical education; Medical research; Mental health; Prescription drugs; Social work, volunteer service, charitable organizations; State and local government operations; Student aid and college costs; Transportation costs; Women's health
Committee report
H. Rept. 119-114